Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas

Abstract Background ERBB-2 is overexpressed in about 20% of breast cancers (BCs), indicating poor prognosis. The receptor activator of nuclear factor-κB (RANK) pathway is implicated in ERBB-2 (+) BC. The purpose of this study was to elucidate the underlying molecular mechanism of this interaction an...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Ilianna Zoi, Michalis V. Karamouzis, Evangelia Xingi, Panagiotis Sarantis, Dimitra Thomaidou, Panayiotis Lembessis, Stamatios Theocharis, Athanasios G. Papavassiliou
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMC 2019-12-01
Serier:	Breast Cancer Research
Fag:	Breast cancer RANK RANKL ERBB family ERBB-2 Dimers
Online adgang:	https://doi.org/10.1186/s13058-019-1226-9
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!